Endocrine Therapy Nonadherence and Discontinuation in Black and White Women
Open Access
- 20 September 2018
- journal article
- research article
- Published by Oxford University Press (OUP) in JNCI: Journal of the National Cancer Institute
- Vol. 111 (5) , 498-508
Abstract
Differential use of endocrine therapy (ET) by race may contribute to breast cancer outcome disparities, but racial differences in ET behaviors are poorly understood. Women aged 20–74 years with a first primary, stage I–III, hormone receptor–positive (HR+) breast cancer were included. At 2 years postdiagnosis, we assessed nonadherence, defined as not taking ET every day or missing more than two pills in the past 14 days, discontinuation, and a composite measure of underuse, defined as either missing pills or discontinuing completely. Using logistic regression, we evaluated the relationship between race and nonadherence, discontinuation, and overall underuse in unadjusted, clinically adjusted, and socioeconomically adjusted models. A total of 1280 women were included; 43.2% self-identified as black. Compared to white women, black women more often reported nonadherence (13.7% vs 5.2%) but not discontinuation (10.0% vs 10.7%). Black women also more often reported the following: hot flashes, night sweats, breast sensitivity, and joint pain; believing that their recurrence risk would not change if they stopped ET; forgetting to take ET; and cost-related barriers. In multivariable analysis, black race remained statistically significantly associated with nonadherence after adjusting for clinical characteristics (adjusted odds ratio = 2.72, 95% confidence interval = 1.75 to 4.24) and after adding socioeconomic to clinical characteristics (adjusted odds ratio = 2.44, 95% confidence interval = 1.50 to 3.97) but was not independently associated with discontinuation after adjustment. Low recurrence risk perception and lack of a shared decision making were strongly predictive of ET underuse across races. Our results highlight important racial differences in ET-adherence behaviors, perceptions of benefits/harms, and shared decision making that may be targeted with culturally tailored interventions.Keywords
Funding Information
- American Cancer Society
- Mentored Research Scholar (MRSG-13–157-01-CPPB)
- Breast Cancer (NIH/NCI P50-CA58223)
- National Cancer Institute (P01CA151135)
- Susan G. Komen Foundation (CCR 15333140)
This publication has 58 references indexed in Scilit:
- Non-initiation of adjuvant hormonal therapy in women with hormone receptor-positive breast cancer: The Breast Cancer Quality of Care Study (BQUAL)Breast Cancer Research and Treatment, 2012
- Decomposing Racial and Ethnic Disparities in the Use of Postacute Rehabilitation CareHealth Services Research, 2011
- Racial/ethnic differences in initiation of adjuvant hormonal therapy among women with hormone receptor-positive breast cancerBreast Cancer Research and Treatment, 2011
- Association Between Prescription Co-Payment Amount and Compliance With Adjuvant Hormonal Therapy in Women With Early-Stage Breast CancerJournal of Clinical Oncology, 2011
- Intrinsic Breast Tumor Subtypes, Race, and Long-Term Survival in the Carolina Breast Cancer StudyClinical Cancer Research, 2010
- Early Discontinuation and Nonadherence to Adjuvant Hormonal Therapy in a Cohort of 8,769 Early-Stage Breast Cancer PatientsJournal of Clinical Oncology, 2010
- Race and triple negative threats to breast cancer survival: a population-based study in Atlanta, GABreast Cancer Research and Treatment, 2008
- Exploring Social Contextual Correlates of Computer Ownership and Frequency of Use Among Urban, Low-Income, Public Housing Adult ResidentsJournal of Medical Internet Research, 2007
- Parity and disparity in first course treatment of invasive breast cancerBreast Cancer Research and Treatment, 2007
- Adherence to tamoxifen over the five-year courseBreast Cancer Research and Treatment, 2006